SCHEMBL17196272

SCHEMBL17196272

CC(C)(C)OC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)CCCCCN1C(=O)C=CC1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 1/20 0.55
▸ MAOA P21397 1/20 0.45
▸ HDAC1 Q13547 5/20 0.43
▸ HDAC6 Q9UBN7 5/20 0.43
▸ MAPT P10636 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ ACE P12821 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ KLK5 Q9Y337 1/20 0.42
▸ MMP1 P03956 1/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP9 P14780 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24191454 0.90 AKT1 (0.59) AKT1HDAC1HDAC6ACEHDAC3
SCHEMBL17003656 0.86 FAAH (0.50) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL20787950 0.86 FAAH (0.50) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL29114311 0.85 FAAH (0.51) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL29235949 0.85 FAAH (0.51) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL25749157 0.85 AKT1 (0.52) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL24344052 0.85 AKT1 (0.52) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL24343455 0.85 AKT1 (0.52) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL25975485 0.84 AKT1 (0.50) AKT1HDAC1HDAC6HDAC3HDAC4
SCHEMBL25967838 0.84 AKT1 (0.50) AKT1HDAC1HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049782-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-02-13 — — US disclosed
US-12186310-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-01-07 — — US disclosed
EP-4464707-A2 ANTI-HER2 ANTIBODY-DRUG CONJUGATE Daiichi Sankyo Company, Limited (JP) 2024-11-20 — — EP disclosed
EP-4212552-B1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO CO LTD (JP) 2024-11-13 — — EP disclosed
US-20240082413-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-03-14 — — US disclosed
US-20240026030-A1 METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-01-25 — — US disclosed
US-11795236-B2 Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-24 — — US disclosed
EP-4212552-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE Daiichi Sankyo Company, Limited (JP) 2023-07-19 — — EP disclosed
US-11633493-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-04-25 — — US disclosed
US-11633493-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-04-25 — — US disclosed
CN-113929738-A Antibody-drug conjugates 第一三共株式会社 2022-01-14 — — CN disclosed
US-10973924-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-04-13 — — US disclosed
US-20200385486-A1 METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-12-10 — — US disclosed
US-20200282073-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-10 — — US disclosed
US-20190077880-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-03-14 — — US disclosed
US-10195288-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-02-05 — — US disclosed
US-9808537-B2 Antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-11-07 — — US disclosed
US-20160333112-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-17 — — US disclosed
US-20160279259-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-29 — — US disclosed
US-20150297748-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11633493-B2 Antibody-drug conjugate LANCL2, LANCL1, LCLAT1 AKT1 3425/4885MAOA 1501/4885HDAC1 1373/4885
US-20240026030-A1 METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE ERBB2, EGFR, H1-2 AKT1 3358/4885MAOA 1062/4885HDAC1 1363/4885
US-20200385486-A1 METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE ERBB2, EGFR, H1-2 AKT1 3287/4885MAOA 1198/4885HDAC1 1333/4885
US-20200282073-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LANCL1, LCLAT1 AKT1 3425/4885MAOA 1501/4885HDAC1 1373/4885
US-20160333112-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE ERBB2, EGFR, H1-2 AKT1 2462/4885MAOA 1485/4885HDAC1 1596/4885
US-10973924-B2 Antibody-drug conjugate LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885
US-10195288-B2 Antibody-drug conjugate LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885
US-20160279259-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885
US-11795236-B2 Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate ERBB2, EGFR, ERBB3 AKT1 3339/4885MAOA 1199/4885HDAC1 1301/4885
US-12186310-B2 Antibody-drug conjugate LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885
US-20240082413-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885
US-20190077880-A1 ANTI-HER2 ANTIBODY-DRUG CONJUGATE ERBB2, EGFR, H1-2 AKT1 2371/4885MAOA 1485/4885HDAC1 1625/4885
US-20250049782-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LCLAT1, LANCL1 AKT1 3051/4885MAOA 1556/4885HDAC1 1407/4885
US-20150297748-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LANCL1, LCLAT1 AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback